How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of DSP-5336 Following a Single Oral Dose in Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Myeloproliferative Neoplasms

The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.

Study Overview

• Status: Recruiting
• Conditions: Advanced Hematologic Malignancies
• Intervention / Treatment: Drug: DSP-5336; Drug: [14C]-DSP-5336

• Study Type: Interventional
• Enrollment (Estimated): 8
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Holly Beever; Phone Number: 774-405-5261; Email: holly.beever@us.sumitomo-pharma.com

Study Locations

• United States
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27514
      • Not yet recruiting
      • University of North Carolina
      • Contact: Joshua Zeidner, MD; Phone Number: 919-966-4432; Email: cancerclinicaltrials@med.unc.edu
  • Texas
    • Houston, Texas, United States, 77030
      • Recruiting
      • MD Anderson Cancer Center
      • Contact: Naval Daver, MD; Phone Number: 713-794-4392; Email: riknott@mdanderson.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male or female, of any race, ≥ 18 years of age. Female patients must be surgically sterile or postmenopausal. Male patients must be permanently sterile or agree to use contraception.
• Have an advanced hematological malignancy that is relapsed, refractory, or has progressed following receipt of standard and available treatments.
• Any prior pre-treatment toxicities resolved to ≤Grade 1 prior to enrolment, with exception of ≤Grade 2 alopecia or neuropathy.
• Adequate kidney and liver function
• ECOG performance status of ≤ 2.
• Able to attend the required study visits, including the confinement period for monitoring and collection of bowel movements and micturition.
• Able to comprehend and are willing to sign the ICF and abide by the study restrictions.

Exclusion Criteria:

• Histologic diagnosis of acute promyelocytic leukemia.
• Abnormal ECG that is clinically significant, such as QTcF > 480 msec. QT interval correction can be performed in the case of bundle branch block.
• History of torsades de pointes.
• Left ventricular ejection fraction ≤ 45%, as determined by echocardiogram.
• Have any concurrent conditions that could pose an undue risk or interfere with interpretation of the study results, including, but not limited to clinically significant non-healing or healing wounds, concurrent congestive heart failure, unstable angina, cardiac arrhythmia requiring treatment (excluding asymptomatic atrial fibrillation), myocardial infarction within 6 months, acute coronary syndrome within 6 months, significant pulmonary disease (shortness of breath at rest or on mild exertion; eg, due to concurrent severe obstructive pulmonary disease, hypertension not controlled with concomitant medication, or diabetes mellitus with > 2 episodes of ketoacidosis in the prior 6 months).
• History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed).
• History or evidence of severe dysphagia, short-gut syndrome, gastroparesis, gastrointestinal tract disease, malabsorption syndrome, the requirement for intravenous alimentation, gastric/jejunal feeds, any uncontrolled gastrointestinal disease, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally, including the inability to swallow oral medication
• Have cognitive, psychological, or psychosocial impediment that would impair their ability to receive therapy according to the protocol or would adversely affect their ability to comply with the informed consent process, protocol, or protocol-required visits and procedures.
• History of bowel obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of check-in, unless approved by the investigator and medical monitor.
• Active and uncontrolled bacterial, viral, or fungal infection requiring parenteral therapy.
• Positive hepatitis panel and/or positive human immunodeficiency virus test indicative of active infection. Patients whose results are compatible with prior immunization may be included.
• Undergone HSCT, chimeric antigen receptor cell therapy, or other modified T-cell therapy within 60 days prior to dosing.
• Received donor lymphocyte infusion within 28 days prior to dosing, receiving immunosuppressive therapy post-HSCT, or have clinically active GVHD or GVHD requiring active medical intervention other than the use of topical steroids for ongoing cutaneous GVHD.
• Received systemic calcineurin inhibitors within 2 weeks prior to dosing.
• Received other anticancer drugs or other investigational treatment within 14 days or 5 half-lives, whichever is shorter, prior to dosing.
• Major surgery within 28 days prior to dosing.
• Any known intolerance or hypersensitivity to components of the study intervention.
• Patients who have previously been dosed in > 2 radiolabeled drug studies in the last 12 months. For patients who have previously been dosed in ≤ 2 radiolabeled drug studies within the last 12 months, the previous radiolabeled dose must be at least 4 months prior to check-in to the study site where exposures are known to the investigator or 6 months prior to check-in to the study site for a radiolabeled drug study where exposures are not known to the investigator.
• Poor peripheral venous access.
• Patients with exposure to significant diagnostic or therapeutic radiation or current employment in a job requiring radiation exposure monitoring within 12 months prior to check-in.
• Patients who, in the opinion of the investigator or designee, should not participate in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: DSP-5336 tablets and [14C]-DSP-5336 solution; Part 1	Drug: DSP-5336; tablet; Drug: [14C]-DSP-5336; oral solution
Experimental: Optional Continued Access; Part 2	Drug: DSP-5336; tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total recovery of radioactivity in urine as percentage of total radioactive dose of [14C]-DSP-5336	The percentage of dose excreted in urine	Day 1 to 4, max 7 days if less than 90% is collected by Day 4
Total recovery of radioactivity in fecal waste as percentage of total radioactive dose of [14C]-DSP-5336	The percentage of dose excreted in fecal waste	Day 1 to 4, max 7 days if less than 90% is collected by Day 4
Total recovery of radioactivity in excreta balance as percentage of total radioactive dose of [14C]-DSP-5336	The percentage of dose excreted in combined urine and fecal waste	Day 1 to 4, max 7 days if less than 90% is collected by Day 4
Relative abundance (mean value) of [14C]-DSP-5336	Plasma samples will be analyzed for [14C]-DSP-5336 and its metabolites.	4 days, max 7 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under the plasma concentration time profile from time zero to time of the last quantifiable concentration (AUClast) of [14C]-DSP-5336	The determination of AUClast using the linear/log trapezoidal rule	4 days, max 7 days
Cmax for the relative bioavailability of [14C]-DSP-5336	Analysis of the maximum concentration (Cmax) of the relative bioavailability of [14C]-DSP-5336 utilizing the ratio of the adjusted geometric means	4 days, max 7 days
t(1/2) of [14C]-DSP-5336	Elimination half-life (t[1/2]) of [14C]-DSP-5336	4 days, max 7 days
Ratio of plasma to whole blood total radioactivity	The fraction of [14C]-DSP-5336 radioactivity associated with whole blood and plasma and with red blood cells and other cellular components of whole blood was determined by using the concentration of [14C]-DSP-5336 radioactivity in whole blood and plasma	4 days, max 7 days
Number of participants with adverse events and serious adverse events	Safety of DSP-5336 by reporting of AEs and SAEs	30 days

Collaborators and Investigators

• Sponsor: Sumitomo Pharma America, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 26, 2026
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): August 1, 2026

Study Registration Dates

• First Submitted: February 6, 2026
• First Submitted That Met QC Criteria: February 24, 2026
• First Posted (Actual): March 2, 2026

Study Record Updates

• Last Update Posted (Actual): April 8, 2026
• Last Update Submitted That Met QC Criteria: April 7, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: DSP-5336-102

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No